StockPreacher.com announces an investment report featuring A.P. Pharma Inc. (Nasdaq:APPA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/APPA
A.P. Pharma Inc. (APPA) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company's primary focus is on its lead product candidate, APF530, which completed a pivotal phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008.
Message Board Search for APPA: http://www.boardcentral.com/boards/APPA
In the report, the analyst notes:
"APPA's net loss for the fourth quarter of 2009 was $1.9 million, or $0.05 per share, compared with a net loss of $3.9 million, or $0.13 per share, for the fourth quarter of 2008. For the full year 2009, the Company's net loss was $10.0 million, or $0.31 per share, versus a net loss of $23.1 million, or $0.75 per share, for 2008. The improved operating results in both the quarter and the year ended December 31, 2009, were principally due to APPA's decision to suspend, for the time being, development of its other product candidates in order to focus its resources on the submission and approval of the NDA for APF530, as well as other cost containment initiatives undertaken by the Company.
"APPA recently said U.S. health regulators did not approve its experimental drug for the treatment of nausea and vomiting induced by chemotherapy (CINV), citing concerns regarding the drug's administration system, and asked for more studies. The specialty pharmaceutical Company does not expect the commercial launch of the drug, APF530, in 2010, based on the expected time needed for a resubmission."
To read the entire report visit: http://www.stockpreacher.com/n/APPA
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels